Preferred Label : velaglucerase alfa, human;
MeSH note : a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher
disease;
Registry Number MeSH : EC 3.2.1.45;
Is substance : O;
UNII : EC 3.2.1.45;
Origin ID : C550184;
UMLS CUI : C2934720;
- ATC code(s)
- Exact mapping(s) to DCI
- MeSH indexing information
- MeSH term(s) associated for indexing
- Record concept(s)
- Semantic type(s)
- Validated automatic mappings to NTBT
https://ansm.sante.fr/tableau-marr/velaglucerase-alfa
2022
false
false
false
France
French
risk management
velaglucerase alfa, human
Velaglucerase Alfa
Velaglucerase Alfa
guidelines for drug use
infusions, intravenous
drug hypersensitivity
infusions, intravenous
continuity of patient care
velaglucerase alfa
patients guideline
patient safety
enzyme replacement therapy
gaucher disease
Infusion-Related Reaction
home nursing
---
https://www.ema.europa.eu/medicines/human/EPAR/Vpriv
2012
United Kingdom
French
English
syndication feed
package leaflet
summary of product characteristics
drug evaluation
infusions, intravenous
gaucher disease
orphan drug production
drug approval
treatment outcome
dna, recombinant
enzyme replacement therapy
pregnancy
breast feeding
adult
child
adolescent
aged
velaglucerase alfa
glucosylceramidase
glucosylceramidase
velaglucerase alfa, human
velaglucerase alfa, human
Gaucher disease type 1
---
http://www.has-sante.fr/portail/jcms/c_1014915/vpriv
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-01/vpriv_-_ct-_9171.pdf
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-09/vpriv_ct_9171.pdf
2010
France
French
English
orphan drug production
gaucher disease
infusions, intravenous
enzyme replacement therapy
glucosylceramidase
velaglucerase alfa
recombinant proteins
treatment outcome
glucosylceramidase
velaglucerase alfa, human
glucosylceramidase
evaluation of the transparency committee
---
http://www.has-sante.fr/portail/jcms/c_1046144/vpriv-velaglucerase-alpha-enzyme-de-substitution
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-01/vpriv_-_ct-_9171.pdf
2010
France
French
treatment outcome
velaglucerase alfa, human
glucosylceramidase
velaglucerase alfa, human
gaucher disease
velaglucerase alfa
enzyme replacement therapy
orphan drug production
glucosylceramidase
infusions, intravenous
glucosylceramidase
evaluation of the transparency committee
guidelines for drug use
---